Analysis: The PATH study may have lost its way on quitting smoking with e-cigs

A study that recently drew attention for concluding that vaping was a less successful cessation method than nicotine replacement therapy (NRT) or even going cold turkey may be undermined by potential flaws.

The researchers chose to depart from the clinical study focus undertaken in other cessation reviews such as the comprehensive and well-regarded Cochrane review. The broad, international Cochrane review suggested with “moderate confidence” that e-cigarettes are not only helpful in getting individuals to stop smoking, they are even more effective than prescription NRT, the current clinical standard.

Read full article
I'm already a subscriber
Author default picture


This article was written by one of ECigIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual vaping markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global e-cigarette market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

ECigIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization